CRP or C-Reactive Protein

Why CRP Still Matters

CRP is one of the most frequently ordered blood tests in medicine, and for good reason. It is quick to run, inexpensive, and reacts fast to whatever is going on in the body. Whether a doctor is checking a suspected infection, tracking a flare of rheumatoid arthritis, or screening for cardiovascular risk, CRP gives a fast readout of the body's inflammatory state.

CRP is also a clean example of the acute-phase response: a single cytokine signal from the site of injury triggers a measurable, predictable change in a distant organ, the liver.

Introduction

C-reactive protein (CRP) is a plasma protein produced by the liver and released into the bloodstream during inflammation. Unlike the erythrocyte sedimentation rate, which measures an indirect physical effect of inflammatory proteins, CRP testing measures the actual concentration of a specific protein in blood [1]. This makes CRP faster and generally more sensitive to acute changes than ESR.

CRP belongs to a family of proteins called pentraxins. Hepatocytes (liver cells) produce it in direct response to inflammatory cytokines, mainly interleukin-6 and, to a lesser extent, interleukin-1β [6]. Because this signaling pathway is quick, CRP is one of the fastest-moving markers available in routine blood testing.

How CRP Works

When tissue is injured or infected, immune cells release cytokines, chiefly IL-6. These cytokines travel to the liver and switch on CRP gene transcription. Within hours, CRP floods into the bloodstream, sometimes reaching concentrations several hundred times the resting level [6].

Standard CRP vs. High-Sensitivity CRP (hs-CRP)

These are not two different molecules. They are two versions of the same test, tuned to different sensitivity ranges [3].

• Standard CRP measures roughly 10–1,000 mg/L. It is the right test when a patient has active symptoms, such as fever or pain, and the question is whether significant inflammation is present.
• hs-CRP can detect concentrations as low as 0.1–0.3 mg/L. It is designed to pick up the low-grade, chronic inflammation linked to cardiovascular disease in people who otherwise look well [8].

The two are not interchangeable, and a standard CRP assay may simply report "less than 10 mg/L" for a sample that an hs-CRP assay could measure precisely at, say, 2.4 mg/L.

Materials

1. Serum separator tube (SST, gold/red-yellow top) or plasma tube (lithium heparin, green top), depending on laboratory validation. Some hs-CRP assays are validated on EDTA plasma as well.
2. Centrifuge capable of producing 1,000–1,300 × g.
3. Automated clinical chemistry analyzer with an immunoturbidimetric or nephelometric CRP module (e.g., Roche Cobas, Beckman Coulter AU series, Siemens BN system).
4. CRP antibody reagent kit (latex-enhanced or plain immunoturbidimetric/nephelometric reagent, matched to standard or high-sensitivity range).
5. Calibrators and internal quality control material (low, normal, and high CRP concentrations), traceable to the WHO/IRMM international CRP reference standard where available.
6. Pipettes and sample cups for analyzer loading.
7. Personal protective equipment.

Protocol

1. Collect venous blood into a serum separator tube or an appropriate plasma tube per the analyzer's validated protocol. No fasting is required for standard CRP; the CDC recommends a fasting sample only when CRP is drawn alongside a lipid panel [4].
2. Allow serum tubes to clot for 30 minutes at room temperature before centrifugation, if using serum.
3. Centrifuge at 1,000–1,300 × g for 10 minutes to separate serum or plasma from cells.
4. Inspect the sample for hemolysis, lipemia, or icterus, since these can interfere with turbidimetric and nephelometric readings [7].
5. Store the separated sample at room temperature if testing within 24 hours, at 2–8°C if testing within 5–7 days, or frozen at –20°C or below for longer storage. Avoid repeated freeze-thaw cycles, which can degrade CRP and affect result accuracy.
6. Label and transport the sample per standard chain-of-custody procedures if sent to an external laboratory.
7. Load the sample onto the automated analyzer.
8. Mix the sample with the CRP antibody reagent. Anti-CRP antibodies bind CRP molecules in the sample, forming immune complexes [7].
9. Measure the resulting turbidity (light blocked as it passes through the sample, in immunoturbidimetry) or light scatter (nephelometry). The analyzer reads the signal photometrically.
10. Calculate the CRP concentration by comparing the signal against a stored calibration curve built from known CRP standards [7].
11. Select the correct assay range. Standard CRP assays are calibrated for roughly 10–1,000 mg/L. If cardiovascular risk assessment or another low-level application is needed, run the high-sensitivity (hs-CRP) assay instead, which extends the lower limit of detection to approximately 0.1–0.3 mg/L [3,8]. The two assays are not interchangeable.
12. Report the result in mg/L or mg/dL as validated by the laboratory (1 mg/dL = 10 mg/L). Flag results above the laboratory's upper reference limit as elevated.
13. Run internal quality control material (low, normal, high) at the start of each run and at defined intervals per laboratory policy, before reporting patient results.
14. Participate in external quality assurance/proficiency testing programs to verify inter-laboratory comparability, since turbidimetric and nephelometric platforms can show measurable differences from each other on the same sample.

Special Considerations for Cardiovascular Risk Testing (hs-CRP)

15. Avoid testing during acute illness. Do not use hs-CRP for cardiovascular risk stratification in patients who are acutely unwell, recently injured, or have an active infection, since results will not reflect baseline risk [1].
16. Repeat and average. Where hs-CRP is used for cardiovascular risk, collect two samples approximately two weeks apart and use the lower or averaged value, per CDC/AHA-informed guidance [4,9].

Reference Ranges and Interpretation

General Reference Range

Most laboratories consider CRP below 10 mg/L (1.0 mg/dL) as the upper limit of normal for the standard assay, though exact cutoffs vary by lab and method [1]. A result above 10 mg/L generally indicates active inflammation somewhere in the body.

These bands are general teaching guides, not diagnostic thresholds. A single CRP value should always be read next to the clinical picture [1].

hs-CRP and Cardiovascular Risk

For assessing cardiovascular risk in otherwise well people, the widely used cutoffs are [4]:

• Low risk: hs-CRP below 1.0 mg/L
• Average risk: hs-CRP 1.0–3.0 mg/L
• High risk: hs-CRP above 3.0 mg/L

Because CRP can be temporarily raised by a cold, minor injury, or recent vaccination, guidance recommends taking two hs-CRP measurements about two weeks apart and averaging them, rather than relying on a single result, when the test is being used for cardiovascular risk stratification [9]. In patients with established atherosclerotic disease, an hs-CRP cutoff of 2.0 mg/L or higher indicates residual inflammatory risk, even when LDL cholesterol is well-controlled on statin therapy [10]. Today, this >2.0 mg/L threshold is an actionable clinical target; cardiologists increasingly use it to prescribe targeted anti-inflammatory therapies, such as low-dose colchicine, to actively reduce the risk of secondary myocardial infarctions and strokes [15,16].

CRP in Chronic Inflammatory Disease

CRP is useful for tracking disease activity in conditions such as rheumatoid arthritis and giant cell arteritis, where rising or falling levels can mirror a flare or a response to treatment [1]. CRP does not rise consistently in every autoimmune condition, though. In systemic lupus erythematosus, for example, CRP often stays low unless there is associated serositis or joint inflammation, while ESR may still be elevated. In scleroderma, polymyositis, and dermatomyositis, CRP typically shows only a modest rise even during active disease [1]. This is an important teaching point: a normal CRP does not exclude an autoimmune flare in these specific conditions.

CRP in Infection and Sepsis

CRP is commonly used to help identify infection and monitor its course. Results above 50 mg/L are associated with bacterial infection in a large majority of cases, though viral infections, trauma, and post-surgical inflammation can also raise CRP substantially [11]. Historically, a CRP above 100 mg/L was considered almost exclusively indicative of bacterial infection; however, the COVID-19 pandemic demonstrated that intense viral cytokine storms can routinely drive CRP well above this threshold without secondary bacterial pneumonia [13].

In suspected sepsis, CRP is frequently compared with procalcitonin (PCT). Across most published comparisons, procalcitonin shows better specificity for bacterial infection and tends to normalize faster with successful treatment, while CRP remains more available and less costly in most laboratories [5]. Neither test replaces blood cultures, and international sepsis guidelines treat both as supporting rather than defining evidence [5]. In practice, many hospitals use the two together: CRP for a broad first look at inflammation, and procalcitonin to help judge whether a bacterial cause is more or less likely. Furthermore, current international guidelines highlight procalcitonin's specific utility in antimicrobial stewardship and it is heavily relied upon to safely decide when to discontinue antibiotics in patients with resolving infections [5,14].

CRP in Pregnancy

CRP rises modestly across a normal pregnancy, most notably in the third trimester. One reference study found a median CRP around 4.1 mg/L in the third trimester, compared to roughly 2.4 mg/L in the first and second trimesters [12]. This physiological rise means pregnancy-specific reference ranges should be used rather than standard adult cutoffs when interpreting CRP in a pregnant patient.

What Can Raise or Lower CRP

Factors That Raise CRP

• Infection (bacterial, viral, or fungal)
• Trauma or recent surgery
• Autoimmune flares (rheumatoid arthritis, giant cell arteritis, inflammatory bowel disease)
• Obesity, which is associated with chronic low-grade inflammation
• Pregnancy, particularly in the third trimester
• Smoking
• Recent vaccination or minor illness (can cause a temporary rise for a few days)

Factors That Can Cause a Falsely Reassuring (Low) Result

• Testing too early, before CRP has had time to rise (within the first 4–6 hours of an insult)
• Certain conditions with limited CRP response, such as SLE without serositis, scleroderma, and dermatomyositis, where CRP may stay low despite active disease [1]
• Corticosteroids and some anti-inflammatory or immunosuppressive medications, which blunt the CRP response

Why CRP and ESR Are Often Ordered Together

CRP and ESR both signal inflammation, but their timing is different enough that ordering both gives a fuller picture. CRP rises and falls quickly, making it useful for tracking how fast a patient is responding to treatment. ESR moves more slowly and stays elevated longer, making it a better marker of a chronic or ongoing process. When the two disagree, for example a high ESR with a normal CRP, it can be a clue pointing toward specific conditions like SLE, where the acute-phase response is blunted despite ongoing inflammation [1].

Frequently Asked Questions (FAQs)

What does a high CRP level mean?

A high CRP means there is inflammation somewhere in the body. It does not identify the cause or the location on its own. Common reasons include infection, injury, surgery, or a flare of an autoimmune condition.

Is there a normal range with no lower limit for CRP?

Yes. Because CRP is a response to inflammation rather than a substance the body always needs, there is no "too low" result. A very low CRP simply means no significant inflammation was detected at the time of the blood draw.

What is the difference between CRP and hs-CRP?

They measure the same protein, but hs-CRP assays can detect much lower concentrations. Standard CRP is used when a patient has active symptoms and the question is whether significant inflammation is present. hs-CRP is used to assess low-grade, chronic inflammation, most often for cardiovascular risk in people without symptoms.

Can CRP diagnose a specific disease?

No. CRP is a non-specific marker. A high CRP tells you inflammation is present, but the same number could come from a cold, a joint flare, or a serious infection. It is a starting point for further evaluation, not a diagnosis by itself.

How quickly does CRP change after treatment starts?

Quickly, compared to most other inflammatory markers. CRP can begin falling within a day or two of effective treatment, because its half-life is only about 19 hours. This makes it useful for checking whether antibiotics or anti-inflammatory treatment are working.

Glossary of Related Medical Terms

• Acute-phase protein — a protein whose blood level changes rapidly during inflammation. CRP is a positive acute-phase protein, meaning its level rises.
• Cytokine — a small signaling protein released by immune cells that coordinates the inflammatory response. Interleukin-6 is the main trigger for CRP production.
• Hepatocyte — a liver cell. Hepatocytes are the primary site of CRP production.
• High-sensitivity CRP (hs-CRP) — a more sensitive version of the CRP assay, able to detect low concentrations relevant to cardiovascular risk.
• Nephelometry — a laboratory technique that measures the amount of light scattered by particles in a solution, used to quantify CRP and other plasma proteins.
• Pentraxin — a family of plasma proteins, including CRP, that play a role in the innate immune response.
• Procalcitonin (PCT) — a separate blood marker, often used alongside CRP, that tends to be more specific for bacterial infection.
• Sepsis — a life-threatening condition caused by the body's extreme response to infection. CRP and procalcitonin are both used to help evaluate suspected sepsis.
• Turbidimetry — a laboratory technique that measures the cloudiness of a solution caused by antibody-antigen clumping, used to quantify CRP.

Disclaimer: This protocol is for educational purposes only. Local laboratory standard operating procedures take precedence. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for clinical decision-making. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Medscape. (2026). C-reactive protein: Reference range, interpretation, collection and panels. Medscape Drugs & Diseases.
2. Medscape. (2026). High-sensitivity C-reactive protein: Reference range, interpretation, collection and panels. Medscape Drugs & Diseases.
3. Testing.com. (2026). C-reactive protein (CRP) test: Order & check levels.
4. Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., 3rd, Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Jr, Taubert, K., Tracy, R. P., Vinicor, F., Centers for Disease Control and Prevention, & American Heart Association (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.cir.0000052939.59093.45
5. Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., Belley-Cote, E., … Levy, M. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive care medicine, 47(11), 1181–1247. https://doi.org/10.1007/s00134-021-06506-y
6. Sproston, N. R., & Ashworth, J. J. (2018). Role of C-Reactive Protein at Sites of Inflammation and Infection. Frontiers in immunology, 9, 754. https://doi.org/10.3389/fimmu.2018.00754
7. Tugirimana, P. L., Holderbeke, A. L., Kint, J. A., & Delanghe, J. R. (2009). A new turbidimetric method for assaying serum C-reactive protein based on phosphocholine interaction. Clinical chemistry and laboratory medicine, 47(11), 1417–1422. https://doi.org/10.1515/CCLM.2009.312
8. Cleveland Clinic. (2022). C-reactive protein (CRP) test.
9. Myers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W., Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan, B. V., Kimberly, M. M., Stein, E. A., Taubert, K. A., Warnick, G. R., Waymack, P. P., CDC, & AHA (2004). CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation, 110(25), e545–e549. https://doi.org/10.1161/01.CIR.0000148980.87579.5E
10. Romeo, F.J., Golino, M., Morello, M. et al. Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: a systematic review and meta-analysis. Sci Rep 16, 8584 (2026). https://doi.org/10.1038/s41598-026-39691-1
11. Singh B, Goyal A, Patel BC. C-Reactive Protein: Clinical Relevance and Interpretation. [Updated 2025 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441843/
12. Wirestam, L., Pihl, S., Saleh, M., Wetterö, J., & Sjöwall, C. (2021). Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. Frontiers in immunology, 12, 722118. https://doi.org/10.3389/fimmu.2021.722118
13. Smilowitz, N. R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J. S., & Berger, J. S. (2021). C-reactive protein and clinical outcomes in patients with COVID-19. European heart journal, 42(23), 2270–2279. https://doi.org/10.1093/eurheartj/ehaa1103
14. Schuetz, P., Wirz, Y., Sager, R., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Kristoffersen, K. B., Burkhardt, O., Welte, T., Schroeder, S., Nobre, V., Wei, L., Bucher, H. C., Bhatnagar, N., Annane, D., … Mueller, B. (2017). Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. The Cochrane database of systematic reviews, 10(10), CD007498. https://doi.org/10.1002/14651858.CD007498.pub3
15. Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., Vida-Simiti, L., … CANTOS Trial Group (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of medicine, 377(12), 1119–1131. https://doi.org/10.1056/NEJMoa1707914
16. Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X. F., Ireland, M. A., Lenderink, T., Latchem, D., Hoogslag, P., Jerzewski, A., Nierop, P., Whelan, A., Hendriks, R., Swart, H., Schaap, J., Kuijper, A. F. M., van Hessen, M. W. J., … LoDoCo2 Trial Investigators (2020). Colchicine in Patients with Chronic Coronary Disease. The New England journal of medicine, 383(19), 1838–1847. https://doi.org/10.1056/NEJMoa2021372